TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.

Snežana MilanovićNina DedicRobert LewDuane BurtonKenneth S KoblanMichael Camilleri Seth C Hopkins

Published in: Diabetes, obesity & metabolism (2024)

Ulotaront delayed the GE of solids in patients with schizophrenia and concurrent MetS with prediabetes. Additional studies are needed to assess whether treatment with TAAR1 agonists is associated with weight loss and glucoregulatory improvement.

Keyphrases

metabolic syndrome
weight loss
locally advanced
bariatric surgery
roux en y gastric bypass
type diabetes
uric acid
cardiovascular disease
rectal cancer
cardiovascular risk factors
case control
combination therapy
body mass index
skeletal muscle